Mineralys Therapeutics, Inc. (MLYS)
| Market Cap | 76.73M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -29.80M |
| Shares Out | 5.17M |
| EPS (ttm) | -5.77 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 247,583 |
| Open | 15.07 |
| Previous Close | 14.87 |
| Day's Range | 14.25 - 15.25 |
| 52-Week Range | 13.52 - 21.98 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 36.92 (+148.62%) |
| Earnings Date | Mar 15, 2023 |
About MLYS
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. [Read more]
Financial Performance
Financial StatementsNews
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
– Lorundrostat pivotal clinical program, for the treatment of patients with uncontrolled hypertension, expected to begin in the first half of 2023 –
Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC
Lorundrostat demonstrated clinically meaningful blood pressure reduction in individuals with uncontrolled hypertension
Mineralys Therapeutics to Announce Fourth Quarter 2022 Financial Results and Host Conference Call on Wednesday, March 15, 2023
RADNOR, Pa., March 01, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abn...
Mineralys Therapeutics Abstracts Selected to be Presented at the American College of Cardiology Annual Scientific Session & Expo Together with the World Congress of Cardiology (ACC.23/WCC) in March 2023
RADNOR, Pa., Feb. 20, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abno...
Mineralys Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
RADNOR, Pa., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abno...
There's a Lot to Love About Mineralys' Valentine's Day IPO
It has been less than a year since Mineralys Therapeutics (NASDAQ: MLYS) listed its IPO, but the activity has been quite hot, particularly since the top of the year. With 2.71 million in trading volum...
Mineralys Therapeutics Announces Pricing of Upsized Initial Public Offering
RADNOR, Pa., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abno...
Mineralys Therapeutics sets IPO terms, which could value the HPV treatment company at nearly $600 million
Mineralys Therapeutics Inc. MLYS, has set terms for its initial public offering, in which the Pennsylvania-based hypertension treatment company looks to raise up to $160 million. the company is offeri...
Mineralys Therapeutics IPO Registration Document (S-1)
Mineralys Therapeutics has filed to go public with an IPO on the NASDAQ.